Precipitated withdrawal is one of the most uncomfortable and misunderstood experiences people can encounter when starting treatment for opioid addiction. It occurs when certain medications rapidly push opioids off receptors in the brain, triggering sudden and severe withdrawal symptoms.
For individuals beginning medication-assisted treatment (MAT), understanding precipitated withdrawal is important because it can affect how and when medications like buprenorphine are started. While the experience can be intense, it is also preventable when treatment is started under proper medical guidance.
What Is Precipitated Withdrawal?
Precipitated withdrawal occurs when a medication abruptly displaces opioids from receptors in the brain and replaces them with a drug that activates those receptors less strongly. This sudden change causes the body to move rapidly from an opioid-dependent state into withdrawal.
The medications most commonly associated with precipitated withdrawal include:
- Buprenorphine (Suboxone, Subutex)
- Long-acting buprenorphine injections such as Sublocade or Brixadi
- Opioid antagonists such as naltrexone (Vivitrol)
These medications are used in treatment because they reduce cravings and help stabilize brain chemistry. However, if they are taken too soon after opioid use, they can trigger rapid withdrawal.
Why Precipitated Withdrawal Happens
To understand precipitated withdrawal, it helps to understand how opioid receptors work. Opioids such as heroin, fentanyl, oxycodone, and morphine attach to mu-opioid receptors in the brain. These receptors control pain relief, mood, and feelings of reward. Buprenorphine works differently from full opioids.
It is known as a partial opioid agonist, meaning it activates opioid receptors but produces a much weaker effect than drugs like heroin or fentanyl. When buprenorphine is introduced while stronger opioids are still attached to receptors, it can push those opioids off the receptors and replace them with a weaker signal. The sudden drop in opioid activity causes withdrawal symptoms to begin rapidly.
Symptoms of Precipitated Withdrawal
Precipitated withdrawal usually begins quickly after medication is taken and can feel more intense than natural withdrawal.
Common symptoms may include:
- Severe body aches
- Nausea and vomiting
- Diarrhea
- Anxiety or panic
- Sweating and chills
- Rapid heart rate
- Restlessness or agitation
- Strong drug cravings
Symptoms can begin within 30 minutes to a few hours after taking the medication and may last several hours before stabilizing.
What Drugs Can Cause Precipitated Withdrawal?
Precipitated withdrawal typically occurs when medications used in opioid treatment are taken too early after opioid use.
Drugs that may cause this include:
- Buprenorphine medications (Suboxone, Subutex)
- Long-acting buprenorphine injections like Brixadi or Sublocade
- Naltrexone medications (oral or injectable Vivitrol)
Naltrexone can cause particularly intense precipitated withdrawal if opioids are still present in the body because it completely blocks opioid receptors.
Does the Naloxone in Suboxone Cause Precipitated Withdrawal?
A common question people ask when learning about medication-assisted treatment is whether the naloxone in Suboxone is responsible for precipitated withdrawal. Precipitated withdrawal can be triggered by several different medications, including opioid antagonists such as naloxone and naltrexone, as well as partial opioid agonists like buprenorphine.
Naloxone is an opioid antagonist, meaning it blocks opioid receptors and rapidly displaces opioids that are already attached to those receptors. This is why naloxone is used in medications like Narcan to reverse opioid overdoses. When naloxone suddenly removes opioids from the receptors in someone who is opioid-dependent, withdrawal symptoms can begin very quickly.
Suboxone contains both buprenorphine and naloxone, but the two ingredients play different roles. Buprenorphine is the primary treatment medication that helps reduce cravings and stabilize opioid receptors. Naloxone is included mainly as an abuse deterrent to discourage injection of the medication.
When Suboxone is taken as prescribed under the tongue, naloxone has very low absorption and typically has little clinical effect. In these cases, precipitated withdrawal is usually associated with the buprenorphine displacing stronger opioids from the receptors if the medication is started too soon after opioid use.
However, opioid antagonists such as naloxone or naltrexone can also cause precipitated withdrawal when administered to someone who still has opioids in their system. This is why individuals starting medications like naltrexone or Vivitrol must wait until opioids are fully cleared from the body before beginning treatment. Understanding the role of these medications helps explain why timing is critical when starting medication-assisted treatment.
Can Kratom Cause Precipitated Withdrawal?
Kratom is sometimes discussed in conversations about opioid withdrawal because its active compounds interact with some of the same receptors in the brain as opioids. The main alkaloids in kratom, mitragynine and 7-hydroxymitragynine, act on the mu-opioid receptors that are involved in pain relief and addiction.
Because of this activity, people who regularly use kratom can develop physical dependence similar to other opioid-like substances. When someone dependent on kratom begins treatment with medications such as buprenorphine or naltrexone, precipitated withdrawal can occur if those medications are started too soon.
Since kratom products vary widely in potency and composition, the timing needed before starting medications like buprenorphine may be difficult to predict. Medical supervision can help reduce the risk of precipitated withdrawal and ensure the safest transition into treatment.
Why Fentanyl Has Increased the Risk
In recent years, precipitated withdrawal has become more common due to the widespread presence of fentanyl in the illicit drug supply.
Fentanyl behaves differently from many other opioids because it:
- Is extremely potent
- Can accumulate in body tissues
- May remain detectable longer than expected
Because of this, individuals may still have fentanyl occupying opioid receptors even after they believe they have waited long enough to begin buprenorphine treatment. This has led many clinicians to adjust induction strategies to reduce the risk of precipitated withdrawal.
How Doctors Prevent Precipitated Withdrawal
Treatment providers use several strategies to avoid precipitated withdrawal when starting MAT. The most common approach involves waiting until a person has entered moderate natural withdrawal before starting buprenorphine. Clinicians often use tools like the Clinical Opiate Withdrawal Scale (COWS) to determine the right time to begin medication.
Other approaches may include:
- Low-dose buprenorphine induction
- Microdosing protocols (sometimes called the Bernese method)
- Careful monitoring during early treatment
These strategies help ensure that opioids have already begun leaving the receptors before medication is introduced.
Figure 1. Example Timelines and Scoring for MAT Buprenorphine Initiation by Opioid Detox Type
Figure 2. Clinical Opiate Withdrawal Scale (COWS)
What Happens If Precipitated Withdrawal Occurs?
Although precipitated withdrawal can feel overwhelming, it is usually temporary. Medical providers may help manage symptoms with supportive treatments such as:
- Anti-nausea medications
- Fluids
- Comfort medications
- Additional monitored buprenorphine dosing in some cases
Symptoms often stabilize within several hours as the body adjusts to the medication.
Precipitated Withdrawal and Medication-Assisted Treatment
Experiencing precipitated withdrawal can be discouraging for someone beginning treatment, but it does not mean medication-assisted treatment will not work.
Medications such as buprenorphine have been shown to:
- Reduce opioid cravings
- Lower overdose risk
- Improve long-term recovery outcomes
When treatment is started under proper medical supervision, the risk of precipitated withdrawal can be significantly reduced.
How to Stop Precipitated Withdrawal
If precipitated withdrawal has already started, the experience can feel intense and overwhelming. Symptoms may appear quickly and can be more severe than typical withdrawal because the opioid receptors in the brain are suddenly displaced.
Although the symptoms can be severe, precipitated withdrawal is usually temporary. The body begins adjusting to the new medication as it stabilizes on the opioid receptors. Medical providers may use several strategies to help manage symptoms and reduce discomfort during this period.
Supportive care may include:
- Anti-nausea medications
- Hydration and electrolyte support
- Medications for anxiety or agitation
- Medications to reduce muscle aches and chills
- Careful monitoring of vital signs
In some cases, clinicians may administer additional buprenorphine doses under supervision. While this may seem counterintuitive, increasing the buprenorphine level can sometimes stabilize receptor activity and reduce symptoms once precipitated withdrawal has already begun.
The most important step is medical supervision. Attempting to manage precipitated withdrawal alone can be extremely uncomfortable and may increase the risk of relapse if someone seeks relief through illicit opioid use. Treatment providers can monitor symptoms and provide supportive care while the body stabilizes.
When to Seek Professional Help
Anyone considering medication-assisted treatment should consult with a medical professional before starting medications like buprenorphine or naltrexone.Attempting to start these medications without guidance can increase the risk of precipitated withdrawal. Professional treatment programs can help determine the safest time to begin medication and provide support during the early stages of recovery.
At Brooks Healing Center, treatment programs address opioid addiction through a combination of evidence-based therapies and medication-assisted treatment when appropriate.
Programs may include:
- Medical detox
- Residential treatment
- Outpatient programs
- Sober living
- Trauma-informed therapy
- Medication-assisted treatment options
Recovery is possible, and professional support can help individuals navigate the challenges that come with starting treatment.
Frequently Asked Questions About Precipitated Withdrawals
What Is Precipitated Withdrawal?
Precipitated withdrawal occurs when a medication suddenly displaces opioids from receptors in the brain, triggering rapid withdrawal symptoms. This most commonly happens when medications like buprenorphine or opioid antagonists are taken too soon after using opioids. The sudden drop in receptor activity causes the body to enter withdrawal much faster than it normally would.
How Long Does Precipitated Withdrawal Last?
Precipitated withdrawal often begins quickly, usually within 30 minutes to a few hours after taking the triggering medication. Symptoms can be intense at first but typically improve within several hours as the body stabilizes on the medication. In some cases, symptoms may last longer depending on the substance involved and the individual’s level of dependence.
Can Subutex Cause Precipitated Withdrawal?
Yes, Subutex (buprenorphine) can cause precipitated withdrawal if it is taken too soon after using opioids such as heroin, fentanyl, or oxycodone. Buprenorphine has a very strong attraction to opioid receptors and can push other opioids off those receptors. If this happens before natural withdrawal has begun, it can trigger rapid withdrawal symptoms.
Can Kratom Cause Precipitated Withdrawal?
Kratom interacts with opioid receptors through compounds such as mitragynine and 7-hydroxymitragynine. If someone who regularly uses kratom begins medications like buprenorphine or naltrexone too soon, those medications can displace kratom’s active compounds from the receptors. This sudden shift can trigger symptoms similar to precipitated withdrawal.
Can Sublocade Cause Precipitated Withdrawal?
Sublocade, a long-acting injectable form of buprenorphine, can cause precipitated withdrawal if it is administered while opioids are still strongly attached to receptors. For this reason, patients are usually stabilized on sublingual buprenorphine before receiving a Sublocade injection to reduce the risk of precipitated withdrawal.
Sources
- Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs, 35(2), 253–259. https://doi.org/10.1080/02791072.2003.10400007
- Tompkins, D. A., Bigelow, G. E., Harrison, J. A., Johnson, R. E., Fudala, P. J., & Strain, E. C. (2009). Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instrument. Drug and Alcohol Dependence, 105(1–2), 154–159. https://doi.org/10.1016/j.drugalcdep.2009.07.001
- Spadaro, A., Long, B., Koyfman, A., & Perrone, J. (2022). Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting. American Journal of Emergency Medicine, 58, 22–26. https://doi.org/10.1016/j.ajem.2022.05.013
- Gregory, C., Yadav, K., Linders, J., Sikora, L., & Eagles, D. (2025). Incidence of buprenorphine-precipitated opioid withdrawal in adults with opioid use disorder: A systematic review. Addiction, 120(1), 7–20. https://doi.org/10.1111/add.16646
- Rosado, J., Walsh, S. L., Bigelow, G. E., & Strain, E. C. (2007). Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100 mg of daily methadone. Drug and Alcohol Dependence, 90(2–3), 261–269. https://pmc.ncbi.nlm.nih.gov/articles/PMC2094723/
- Huhn, A. S., Hobelmann, J. G., Oyler, G. A., & Strain, E. C. (2020). Protracted renal clearance of fentanyl in persons with opioid use disorder. Drug and Alcohol Dependence, 214, 108147. https://doi.org/10.1016/j.drugalcdep.2020.108147
- Pergolizzi, J. V., Jr., Raffa, R. B., & Taylor, R., Jr. (2023). Fentanyl absorption, distribution, metabolism, and excretion (ADME): Narrative review and clinical significance related to illicitly manufactured fentanyl. Journal of Clinical Pharmacy and Therapeutics, 48(3), 468–478. https://pmc.ncbi.nlm.nih.gov/articles/PMC10593981/
- Randhawa, P. A., Brar, R., & Nolan, S. (2020). Buprenorphine-naloxone “microdosing”: An alternative induction approach for the treatment of opioid use disorder in the wake of North America’s increasingly potent illicit drug market. CMAJ, 192(3), E73. https://pmc.ncbi.nlm.nih.gov/articles/PMC6970598/
- Kruegel, A. C., Gassaway, M. M., Kapoor, A., Váradi, A., Majumdar, S., Filizola, M., Javitch, J. A., & Sames, D. (2019). 7-Hydroxymitragynine is an active metabolite of mitragynine and a key mediator of its analgesic effects. ACS Central Science, 5(6), 992–1001. https://pmc.ncbi.nlm.nih.gov/articles/PMC6598159/
- Boyer, E. W., Babu, K. M., Adkins, J. E., McCurdy, C. R., & Halpern, J. H. (2008). Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction, 103(6), 1048–1050. https://pmc.ncbi.nlm.nih.gov/articles/PMC3670991/
- Hämmig, R., Kemter, A., Strasser, J., von Bardeleben, U., Gugger, B., Walter, M., Dürsteler, K., & Vogel, M. (2016). Use of microdoses for induction of buprenorphine treatment with overlapping full opioid agonist use: The Bernese method. Substance Abuse and Rehabilitation, 7, 99–105. https://pmc.ncbi.nlm.nih.gov/articles/PMC4959756/
